Succinylcholine for Rapid Sequence Intubation in Head Injury Patients
Succinylcholine can be used for rapid sequence intubation in acute head injury patients, but rocuronium is the safer choice in patients with severe traumatic brain injury (TBI). The 2023 Society of Critical Care Medicine guidelines suggest administering either rocuronium or succinylcholine when there are no known contraindications to succinylcholine 1.
Key Decision Point: Severity of Brain Injury
The critical factor determining neuromuscular blocker selection is injury severity:
Severe TBI (head abbreviated injury score ≥4): Avoid succinylcholine. A retrospective study of 233 ED patients found succinylcholine was associated with significantly increased mortality in severe TBI (44% vs 23% with rocuronium; OR 4.10,95% CI 1.18-14.12) 2. Rocuronium is preferred in this population.
Mild-to-moderate TBI (head abbreviated injury score <4): Either agent is acceptable. The same study showed no mortality difference between succinylcholine and rocuronium in less severe injuries (14% vs 22%; OR 0.75,95% CI 0.29-1.92) 2.
Dosing Recommendations
Adults
Standard dose: 0.6 mg/kg IV 3
- FDA-approved range: 0.3-1.1 mg/kg
- The traditional 1.0 mg/kg dose is excessive for most patients
- Lower doses (0.5-0.6 mg/kg) provide comparable intubating conditions with shorter apnea times 4, 5
- Doses below 0.5 mg/kg increase risk of unacceptable intubating conditions 4, 5
Pediatric Patients
- Emergency intubation: 2 mg/kg IV for infants and small children 3
- Older children/adolescents: 1 mg/kg IV 3
Critical Safety Considerations
Absolute Contraindications in Head Injury
The FDA label warns to use succinylcholine with GREAT CAUTION in patients during the acute phase following major trauma 3. Specific concerns include:
- Hyperkalemia risk: Peaks at 7-10 days post-injury but timing is variable 3
- Increased intracranial pressure: Theoretical concern, though definitive evidence in acute TBI is lacking 6
- Bradycardia/asystole: Higher risk with repeat dosing; consider atropine pretreatment 3
Mandatory Requirements
- Always administer a sedative-hypnotic induction agent before succinylcholine 1, 3
- Have immediate airway management capabilities and resuscitation equipment available 3
- Confirm proper drug selection to avoid fatal medication errors 3
Practical Algorithm
Assess TBI severity (clinical exam, mechanism, imaging if available)
Severe TBI suspected?
- YES → Use rocuronium 1.2 mg/kg
- NO → Either agent acceptable; succinylcholine offers faster recovery
Check for succinylcholine contraindications:
- Known hyperkalemia or electrolyte abnormalities
7 days post-major trauma/burns/denervation
- Known plasma cholinesterase deficiency
- Malignant hyperthermia history
- Penetrating eye injury (relative)
If using succinylcholine:
- Administer induction agent (etomidate 0.2-0.3 mg/kg or ketamine 1-2 mg/kg)
- Give succinylcholine 0.6 mg/kg IV (adults) or 1-2 mg/kg (pediatrics)
- Intubate at 60 seconds
- Monitor for bradycardia
Evidence Quality and Nuances
The guideline recommendation is conditional with low-quality evidence 1. The most compelling recent data comes from a 2016 single-center retrospective study showing harm with succinylcholine in severe TBI 2, though this has methodological limitations including selection bias. A 2026 multicenter database study of 26,884 patients found lower mortality with succinylcholine overall 7, but this was not specific to TBI patients and included all ED intubations.
The concern about succinylcholine increasing intracranial pressure remains controversial—no definitive evidence exists in acute TBI patients, though studies in elective neurosurgery patients show modest ICP increases 6.
Common Pitfalls
- Using 1.0 mg/kg routinely: This dose is excessive and prolongs apnea unnecessarily 4, 5
- Forgetting induction agent: Never paralyze an awake patient 1, 3
- Ignoring injury timeline: Hyperkalemia risk increases after the acute phase (>7 days) 3
- Repeat dosing without atropine: Bradycardia risk is substantially higher with second doses 3